Author:
Hunter Samuel F.,Bowen James D.,Reder Anthony T.
Funder
Novartis Pharmaceuticals Corporation (US)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference125 articles.
1. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158(5):1173–82.
2. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
3. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84–105.
4. Food and Drug Administration. Gilenya US prescribing information. Revised August 2015. 2010 [cited 29 September 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022527s019lbl.pdf .
5. European Medicines Agency. Gilenya EU summary of product characteristics, latest update of May 2015. 2011 [cited 16 June 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf .
Cited by
107 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献